Dae-Woong Cho
Chief Executive Officer presso CELLIVERY THERAPEUTICS, INC.
Patrimonio netto: 26 M $ in data 31/03/2023
Profilo
Dae-Woong Cho was the founder of ProCell Therapeutics, Inc. (founded in 2005) where he held the title of President & Chief Executive Officer from 2010 to 2012.
He is also the founder of Cellivery Therapeutics, Inc. (founded in 2014) where he currently holds the titles of CEO, Director & Research Director.
Dr. Cho's former job(s) include working as a Principal at Vanderbilt University, Yuhan Corp., GenoCheck Co., Ltd., and Chonnam National University.
Dr. Cho's education history includes a doctorate degree from Vanderbilt University in 2005 and a graduate degree from Hanyang University in 1992.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CELLIVERY THERAPEUTICS, INC.
13.40% | 30/06/2023 | 4 899 454 ( 13.40% ) | 26 M $ | 31/03/2023 |
Posizioni attive di Dae-Woong Cho
| Società | Posizione | Inizio |
|---|---|---|
| CELLIVERY THERAPEUTICS, INC. | Chief Executive Officer | 28/08/2014 |
Precedenti posizioni note di Dae-Woong Cho
| Società | Posizione | Fine |
|---|---|---|
ProCell Therapeutics, Inc.
 ProCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ProCell Therapeutics, Inc. develops protein-based therapeutics. It handles the research and development of biotherapeutics capable of entering cells through proprietary Macromolecule Intracellcellular Transduction Technologies (MITT) using a line-up of Macromolecule Transduction Domain (MTD). The company was founded on December 12, 2005 and is headquartered in Seoul, South Korea. | Founder | - |
| Chonnam National University | Corporate Officer/Principal | - |
| YUHAN CORPORATION | Corporate Officer/Principal | - |
GenoCheck Co., Ltd.
 GenoCheck Co., Ltd. Medical SpecialtiesHealth Technology GenoCheck Co., Ltd. is a holding company, which conducts research in biotechnology and offers products and services related to genes. Its activities include exploring and testing of genes related to human diseases, developing diagnostic deoxyribonucleic acid (DNA) chip and new drugs. The firm's products include microarray, ribonucleic acid stabilization solution, and DNA extraction kit. The company was founded on May 1, 2000 and is headquartered in Seoul, South Korea. | Corporate Officer/Principal | - |
| Vanderbilt University | Corporate Officer/Principal | - |
Formazione di Dae-Woong Cho
| Vanderbilt University | Doctorate Degree |
| Hanyang University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| YUHAN CORPORATION | Health Technology |
| Aziende private | 3 |
|---|---|
GenoCheck Co., Ltd.
GenoCheck Co., Ltd. Medical SpecialtiesHealth Technology GenoCheck Co., Ltd. is a holding company, which conducts research in biotechnology and offers products and services related to genes. Its activities include exploring and testing of genes related to human diseases, developing diagnostic deoxyribonucleic acid (DNA) chip and new drugs. The firm's products include microarray, ribonucleic acid stabilization solution, and DNA extraction kit. The company was founded on May 1, 2000 and is headquartered in Seoul, South Korea. | Health Technology |
ProCell Therapeutics, Inc.
ProCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ProCell Therapeutics, Inc. develops protein-based therapeutics. It handles the research and development of biotherapeutics capable of entering cells through proprietary Macromolecule Intracellcellular Transduction Technologies (MITT) using a line-up of Macromolecule Transduction Domain (MTD). The company was founded on December 12, 2005 and is headquartered in Seoul, South Korea. | Health Technology |
| Cellivery Therapeutics, Inc. |
- Borsa valori
- Insiders
- Dae-Woong Cho
